Alzamend Neuro Inc
ALZN | NASDAQ
$1.94
+$0.05 (+2.65%)
At close: Sep 21, 2026, 4:00 PM ET
$1.93
-$0.01 (-0.52%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2026 Apr 29, 2026 | FY 2025 Apr 29, 2025 | FY 2024 Apr 29, 2024 | FY 2023 Apr 29, 2023 | FY 2022 Apr 29, 2022 | FY 2021 Apr 29, 2021 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -8.77M | -4.5M | -9.94M | -14.87M | -12.32M | -4.95M |
Interest Income | 1.08K | n/a | n/a | n/a | n/a | 1.71K |
Pretax Income | -8.77M | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M |
Net Income | -8.77M | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M |
Selling & General & Admin | 5.14M | 3.08M | 3.48M | 7.42M | 7.12M | 3.64M |
Research & Development | 3.63M | 1.41M | 6.46M | 7.45M | 5.2M | 1.31M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 8.77M | 4.5M | 9.94M | 14.87M | 12.32M | 4.95M |
Interest Expense | -6.62K | 18.03K | 10.1K | 7.7K | 46.52K | 158.8K |
Selling & Marketing Expenses | n/a | 347.3K | 247.33K | 742.6K | 17.65K | n/a |
Cost & Expenses | 8.77M | 4.5M | 9.94M | 14.87M | 12.32M | 4.95M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 3.34M | 398K | 75K | 72K | 65K | 53K |
Shares Outstanding (Diluted) | 3.34M | 450.8K | 75.17K | 72.24K | 66K | 53.82K |
EPS (Basic) | -2.63 | -11.32 | -132.33 | -205.97 | -187.31 | -93.78 |
EPS (Diluted) | -2.63 | -11.32 | -132.33 | -205.97 | -187.31 | -93.78 |
EBITDA | -8.66M | -4.45M | -9.89M | -14.85M | -12.31M | -4.95M |
EBIT | -8.77M | -4.5M | -9.94M | -14.87M | -12.32M | -4.95M |
Depreciation & Amortization | 110.74K | 50.74K | 50.74K | 23.07K | 3.55K | n/a |
Add to Watchlist
Select watchlists to add or remove ALZN